Triazavirin

DB15622InvestigationalSmall molecule

Triazavirin is an antiviral used to treat several strains of influenza. Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain.

Chemical structure of Triazavirin
Mechanism
Curator reviewed · 2 references
Primary indication
Triazavirin was developed in Russia as a potential treatment of Influenza A and B infections.Curator reviewed
Formula / weight
C5H4N6O3S · 228.19 g/mol (avg)
Also known as
Riamilovir

Resolves to

Compound
UNIIF2HTG1MH2DCAS123606-06-4ChEMBLCHEMBL1618116
Clinical / RWD
ATCJ05AX32
Structure
InChIKeyIDVQGNMSSHPZSJ-UHFFFAOYSA-NSMILESCSC1=NN2C(NN=C(C2=O)[N+]([O-])=O)=N1
Targets
P0DTD1rep

What you can answer from here — as of September 24, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 6 drug categories
Sign in
9+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Triazavirin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In